Central Role for Interleukin-2 in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes presents clinically with overt hyperglycemia resulting from progressive immune-mediated destruction of pancreatic β-cells and associated metabolic dysfunction. Combined genetic and immunological studies now highlight deficiencies in both the interleukin-2 (IL-2) receptor and its downstream signaling pathway as a central defect in the pathogenesis of type 1 diabetes. Prior intervention studies in animal models indicate that augmenting IL-2 signaling can prevent and reverse disease, with protection conferred primarily by restoration of regulatory T-cell (Treg) function. In this article, we will focus on studies of type 1 diabetes noting deficient IL-2 signaling and build what we believe forms the molecular framework for their contribution to the disease. This activity results in the identification of a series of potentially novel therapeutic targets that could restore proper immune regulation in type 1 diabetes by augmenting the IL-2 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608 · cited 1×
“In 1995, the rediscovery of Tregs led to a paradigm shift in the field of autoimmunity research with the notion that immune tolerance could be generated by bolstering their activity (29).”
BackgroundCentral Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Yang, X.-P., Ghoreschi, K., Steward-Tharp, S. M., Rodriguez-Canales, J., Zhu, J., Grainger, J. R., Hirahara, K., Sun, H.-W., Wei, L., Vahedi, G., et al. (2011) · Nature Immunology · doi:10.1038/ni.1995 · Cited by 583 · cited 1×
“Counterregulation of IL-2–dependent genes has been demonstrated in Th17 cells, in that IL-2 signaling through STAT5 directly competed with STAT3 binding to conserved target loci, prohibiting their activity (25).”
BackgroundLiao, W., Lin, J.-X., Wang, L., Li, P., & Leonard, W. J. (2011) · Nature Immunology · doi:10.1038/ni.2030 · Cited by 474
Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
McClymont, S. A., Putnam, A. L., Lee, M. R., Esensten, J. H., Liu, W., Hulme, M. A., Hoffmüller, U., Baron, U., Olek, S., Bluestone, J. A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003099 · Cited by 428 · cited 1×
“Likewise, we recently reported that patients with type 1 diabetes exhibit increased frequencies of g interferonFoxP3 T cells in peripheral blood (27).”
BackgroundSelf-citationRother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133 · cited 1×
“However, Daclizumab treatment did not alter clinical outcomes or result in increased inflammation either in combination with mycophenolate mofetil in new-onset type 1 diabetes patients (44) or with Exenatide in subjects with longstanding disease (45).”
Background
Cited by
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
“The other cytokines stromal cell–derived factor 1 αβ , IL-2, IL-4, and CCL22 are each implicated in resolution of pancreatic β cell inflammation 50–53 and stromal cell– derived factor 1 αβ , IL-2, and IL-4 are additionally upregulated in plasma from type 2 DM individuals.”
Hartemann, A., Bensimon, G., Payan, C. A., Jacqueminet, S., Bourron, O., Nicolas, N., Fonfrede, M., Rosenzwajg, M., Bernard, C., & Klatzmann, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70113-x · Cited by 428
From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines
Banchereau, J., Pascual, V., & O'Garra, A. (2012) · Nature Immunology · doi:10.1038/ni.2406 · Cited by 401
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach
Emig, D., Ivliev, A., Pustovalova, O., Lancashire, L., Bureeva, S., Nikolsky, Y., & Bessarabova, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060618 · Cited by 241
CD4 T cell differentiation in type 1 diabetes
Walker, L. S. K., & von Herrath, M. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12672 · Cited by 181
Pesenacker, A. M., Wang, A. Y., Singh, A., Gillies, J., Kim, Y., Piccirillo, C. A., Nguyen, D., Haining, W. N., Tebbutt, S. J., Panagiotopoulos, C., et al. (2016) · Diabetes · doi:10.2337/db15-0572 · Cited by 69
Evolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44
Metadata
- Authors
- Hulme, M. A., Wasserfall, C. H., Atkinson, M. A., & Brusko, T. M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-12-12
- Volume
- 61
- Issue
- 1
- Pages
- 14-22
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2020025403
- Cited by
- 139
- References
- 6
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.